Upadacitinib, a JAK1-selective inhibitor, was studied head to head against adalimumab and placebo in rheumatoid arthritis after an inadequate response to methotrexate, and shown to be superior to ADA and PBO in ACR20 and DAS remission level responses.
Dr. John Cush RheumNow
7 years 3 months ago
Its been 30-40 years since the "House of God" by Samuel Shem changed your medical thinking, if not humor. Check out Dr. Len Calabrese's recollections and call to join his summer book club and add some commentary!! https://t.co/L8wiGpWk42
Dr. John Cush RheumNow
7 years 3 months ago
A review of 376 FDA advisory panels between 2008-15, finds that 22% of FDA’s final actions were discordant with an advisory panels recommendations (moreso w/ safety panels). Of these, 3/4 lead to more restrictive actions and 1/4 less restrictive decisions https://t.co/AK7KbwN2l5
Dr. John Cush RheumNow
7 years 3 months ago
Analysis of 149 OA and 203 RA pts from Rush Univ Rheum Clinic showed the same disease burden (by RAPID3) betw OA & A at initial visits, but after 6 mos. RAPID3 was more improved in RA patients than OA patients (P < 0.001). https://t.co/fNQ2ncJScI
Systemic lupus erythematosus (SLE) patients who are hospitalized have an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) and its individual phenotypes of coronary artery disease (CAD), peripheral artery disease (PAD), and cerebrovascular disease.
Dr. John Cush RheumNow
7 years 3 months ago
Analysis #osteoarthritis clinical trials placebo response ratio (PRR) as the placebo to treatment effect size ratio. PRR was best for walking time/distance (0.30, 95% CI 0.16 to 0.43) and worst for PRO pain (0.44, 95% CI 0.23 to 0.65) https://t.co/4VorQdSIV2
The House of God is probably more known of than read, with over 3 million copies sold since its release when I was a Chief Medical Resident in the era of its writing. The book itself, according to the author Samuel Schem (aka Steven Bergman, MD, DPhil), a psychiatrist and currently Professor of Humanities at NYU, is a true account of his internship, albeit laden with some liberties of fiction - and it's been quoted for generations. The House of
Dr. John Cush RheumNow
7 years 3 months ago
RheumNow Podcast is up! Discussing MAS, CBD, CCP in PsA, Cost savings w/ LLDAS, lupus pregnancy and no go on NGF. View here>> https://t.co/zUclX3ISIs or listen on iTunes or SoundCloud>> https://t.co/DVw7Trrh5r
Dr. John Cush RheumNow
7 years 3 months ago
ER study from 2015-17 shows that among 456 #gout patients, 28.3%) received opioid at discharge; 80% of these were new. Average dose was 38mg morphine equivalent for a median of 8 days - more likely w/ polyarticular gout, hx diabetes & hx prior opioids https://t.co/xf2jD1i4hg
Peter Nash drpnash
7 years 3 months ago
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate:- Arthritis & Rheumatology - second Jak to beat the gold standard!
The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.
Dr. John Cush RheumNow
7 years 3 months ago
Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19.0%. Steroid sparing variable, high infx rates. https://t.co/Ff9KULlKVD
The NEJM has reported that rituximab (RTX) and cyclosporine (CYA) was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months.
Dr. John Cush RheumNow
7 years 3 months ago
Swedish registry comparison of 541 PsA 40944 non-PsA pregnancies between 1997-2014, shows PsA pregnancies had increased risks for preterm birth (adj OR 1.63) and caesarean deliveries (OR 1.47), but no increased risks for pre-eclampsia, stillbirth https://t.co/L5GcNVbjgQ
Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.
